Cargando…

Homologous recombination proficiency in ovarian and breast cancer patients

Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) poly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creeden, Justin Fortune, Nanavaty, Nisha S., Einloth, Katelyn R., Gillman, Cassidy E., Stanbery, Laura, Hamouda, Danae M., Dworkin, Lance, Nemunaitis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555001/ https://www.ncbi.nlm.nih.gov/pubmed/34711195 http://dx.doi.org/10.1186/s12885-021-08863-9

Ejemplares similares

Resident Memory T Cells and Their Effect on Cancer
por: Craig, Daniel J., et al.
Publicado: (2020)

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
por: Devanaboyina, Monika, et al.
Publicado: (2022)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
por: Nemunaitis, John, et al.
Publicado: (2023)

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies
por: Einloth, Katelyn R., et al.
Publicado: (2023)

Current Ovarian Cancer Maintenance Strategies and Promising New Developments
por: Gogineni, Vinaya, et al.
Publicado: (2021)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors
por: Vellani, Shahnaz D., et al.
Publicado: (2023)

Adenomatous polyposis coli in cancer and therapeutic implications
por: Noe, Olivia, et al.
Publicado: (2021)

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
por: Zielli, Teresa, et al.
Publicado: (2023)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2017)

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2020)

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
por: Pai Bellare, Ganesh, et al.
Publicado: (2021)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer – Navigating maintenance therapy for homologous recombinant proficient ovarian cancer
por: Goldsberry, Whitney N., et al.
Publicado: (2022)

Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells
por: de Rugy, T. Goullet, et al.
Publicado: (2016)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition
por: Li, Yangyang, et al.
Publicado: (2022)

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
por: Tao, Lei, et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Antioxidant and Anti-Tumor Effects of Dietary Vitamins A, C, and E
por: Didier, Alexander J., et al.
Publicado: (2023)

ATR inhibition reverses the resistance of homologous recombination deficient MGMT(low)/MMR(proficient) cancer cells to temozolomide
por: El Touny, Lara H., et al.
Publicado: (2021)

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells
por: Wang, Hongge, et al.
Publicado: (2020)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells
por: Muñoz, Meilen C., et al.
Publicado: (2014)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
por: Romeo, Margarita, et al.
Publicado: (2018)

Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma
por: Matsushita, Hirokazu, et al.
Publicado: (2020)

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination
por: Setton, Jeremy, et al.
Publicado: (2021)

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
por: Morand, Susan, et al.
Publicado: (2020)

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition
por: Cavallo, Francesca, et al.
Publicado: (2012)

Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
por: Siddiqui, Arafat, et al.
Publicado: (2021)

Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e298j84h069825llf2v0tdtjtm